Cite
HARVARD Citation
Jones, A. et al. (2017). A comparison of the efficacy and tolerability of the PCSK9 inhibitors, Alirocumab and evolocumab, in routine lipid clinic practice. Atherosclerosis. pp. e247-. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Jones, A. et al. (2017). A comparison of the efficacy and tolerability of the PCSK9 inhibitors, Alirocumab and evolocumab, in routine lipid clinic practice. Atherosclerosis. pp. e247-. [Online].